An article in the Oct. 31, 1996 issue of BioWorld Today on clot-busters vs. angioplasty (p. 2) should have said that doctors usethrombolytics as a primary therapy for heart attack victims and thatActivase has about 80 percent of the market share for thrombolytics.

(c) 1997 American Health Consultants. All rights reserved.